首页 > 市场调查报告书 > 製药

癌症分子标靶治疗学

市场调查报告书

商品编码

1593543

Claudin18.2标靶治疗的全球市场:市场预测和临床试验趋势(2029年)

Global Claudin 18.2 Targeted Therapy Market Forecast & Clinical Trials Insight 2029

出版日期: 2024年11月01日 | 出版商:

KuicK Research | 英文 240 Pages | 商品交期: 最快1-2个工作天内

价格

简介目录图表

紧密连接蛋白 18.2 (CLDN18.2) 是紧密连接蛋白家族成员紧密连接蛋白 18 的一种同工型。它在正常组织中的表达有限，但经常在多种原发性恶性肿瘤中异常表达，包括胃癌、胃食道连接部肿瘤、卵巢肿瘤和其他实体肿瘤。这项发现促成了旨在抑制claudin-18.2来治疗这些癌症（主要是胃癌）的标靶疗法的开发。截至 2024 年 11 月，一种此类治疗方法已获批准，另外几种治疗方法正在开发中。世界各地的製药公司都大力投资这一前景广阔的领域，治疗方法涵盖多个药物类别。这些努力凸显了claudin-18.2标靶治疗改变胃癌治疗前景的潜力，使其成为未来几年值得密切关注的研究领域。

Vyloy（zolbetuximab）于2024年3月获批，是首个针对紧密连接蛋白18.2的药物，标誌着该领域的一个重要里程碑。 Vyloy 由 Ganymed Pharmaceuticals 开发，后来被安斯泰来製药收购，已在美国、欧盟和日本等主要国家获批与化疗联合作为 HER2 阴性 G/GEJ 腺癌（肿瘤表达紧密连接蛋白 18.2）患者的一线治疗。此外，预计该疗法将于 2024 年底在中国获得批准，这将标誌着该疗法在全球范围内的推广，并使其成为这些恶性肿瘤的重要治疗选择。

Vyloy 在美国销售数据显示该疗法广受欢迎，预计到 2024 年第三季末销售额将超过 700 万美元。不断增长的市场渗透率表明，该领域对有效治疗的需求尚未得到满足，而且 claudin 18.2 作为标靶具有强大的治疗潜力。目前，佐贝妥昔单抗正处于临床开发阶段，旨在探索其与各种治疗方案的联合应用，以及在 G/GEJ 腺癌以外的肿瘤（如胰腺癌）中的潜在应用。这些扩展可能会扩大针对 claudin-18.2 的药物的范围和影响。

除 Vyloy 外，还有许多针对 claudin-18.2 的药物正在开发中，包括单株抗体、双特异性抗体、CAR-T 细胞疗法和抗体药物偶联物 (ADC)。其中五种候选药物已进入 3 期临床试验，大多数针对 G/GEJ 恶性肿瘤，但在包括卵巢癌和肺癌在内的其他肿瘤类型中也取得了可喜的成果。如此多样化的治疗选择凸显了针对 claudin-18.2 在肿瘤学中日益增长的兴趣和潜力。

展望未来，由于目前治疗方法的良好表现和不断增长的产品线，claudin 18.2 标靶治疗市场预计将进一步扩大。虽然 G/GEJ 恶性肿瘤仍然是主要关注点，但探索其他适应症可能会扩大这些疗法的使用范围。市场的全球性，既有西方公司，也有亚洲公司，培育了一种协作而又竞争的氛围，可能会促进进一步的创新。随着更多治疗方法的开发和批准，以及伴随诊断的普及，claudin-18.2标靶疗法对癌症治疗的影响可能会显着扩大，为难以治疗的癌症患者带来新的希望。

本报告提供全球Claudin18.2标靶治疗市场相关调查，提供市场概要，以及药物趋势，临床试验趋势，各地区趋势，及加入此市场的主要企业竞争情形等资讯。

Abpro Therapeutics
Antengene Corporation
Arovella Therapeutics
Astellas Pharma
AstraZeneca
Beijing Mabworks Biotech
Biotheus
CARsgen
Dragonboat Biopharmaceutical
Gracell Biotechnology
Harbour BioMed
Innovent Biologics
Klus Pharma
L and L Biopharma
LaNova Medicines Limited
Leap Therapeutics
Luye Pharma Group
Nanjing Bioheng Biotech
Nanjing KAEDI Biotech
OriCell Therapeutics
Shanghai Junshi Biosciences
SparX Biopharmaceutical
TORL Biotherapeutics
Transcenta Holding

简介目录图表

Global Claudin 18.2 Targeted Therapy Market Forecast & Clinical Trials Insight 2029 Report Highlights:

Global & Regional Market Trends Insight
Currently Only 1 Claudin 18.2 Targeted Drug Is Approved: Vyloy (zolbetuximab)
Approved Drug Dosage, Pricing & Sales Insight
Claudin 18.2 Therapy Clinical Trends & Innovations by Indication
Number Claudin 18.2 Drugs In Clinical Trials: > 60 Drugs
Global Claudin 18.2 Drugs Clinical Trials By Company, Indication & Phase
Insight On Technical & Clinical Platforms For Developing Advanced Claudin 18.2 Therapy

Claudin18.2 (CLDN18.2) is an isoform of Claudin18, a member of the tight junction protein family. It serves as a highly selective biomarker, exhibiting limited expression in normal tissues but often showing abnormal expression in various primary malignancies, including gastric cancer, gastroesophageal junction cancer, ovarian cancer, and a few other solid tumors. This finding has led to the development of targeted therapies aimed at inhibiting Claudin18.2 for treating these cancers, majorly gastric cancers. As of November 2024, one such therapy has been approved, with several others in advanced stages of development. Pharmaceutical companies around the world are investing heavily in this promising field, with treatments spanning a range of drug classes. These efforts underscore the potential of Claudin18.2-targeted therapies to transform the treatment landscape for gastric cancer, making this area of research one to watch closely in the coming years.

The approval of Vyloy (zolbetuximab) in March 2024 marked a significant milestone in the field, as it is the first medication to target Claudin18.2. Vyloy, developed by Ganymed Pharmaceuticals and later acquired by Astellas Pharma, has already been approved in major countries, such as the US, the EU, and Japan, for use in combination with chemotherapy as the first-line treatment of patients with HER2-negative G/GEJ adenocarcinoma whose tumors express Claudin18.2. Additionally, the anticipated approval in China by the end of 2024 suggests a global expansion of this therapy, establishing it as a crucial treatment option for these aggressive tumors.

Sales data for Vyloy has indicated a strong adoption, with the therapy's sales surpassing US$ 7 Million by the end of the third quarter of 2024. This increasing market penetration demonstrates both the unmet need for effective treatments in this domain and Claudin18.2's strong therapeutic potential as a target. Zolbetuximab is now in clinical development, with trials investigating its application in combination with various therapy regimens as well as potential applications in tumors other than G/GEJ adenocarcinoma, such as pancreatic carcinoma. These expansions may extend the spectrum and impact of Claudin18.2-targeted medicines.

Aside from Vyloy, numerous other Claudin18.2-targeting medicines are under development, including monoclonal antibodies, bispecific antibodies, CAR-T cell therapies, and antibody-drug conjugates (ADCs). Five of these candidates are already in phase 3 clinical trials, largely for G/GEJ malignancies, but research is showing promise in other tumor types, including as ovarian and lung cancers. This varied pipeline of treatment options highlights the increased interest and potential for targeting Claudin18.2 in oncology.

The competitive landscape for Claudin18.2-targeting therapies is becoming more dynamic, with major corporations investing in research and development. China, in particular, has emerged as a hub of innovation in this field, with numerous companies, including Innovent, MabWorks, and Biotheus, making substantial progress in developing Claudin18.2-targeting medicines.

Companion diagnostic tests are an important element of the Claudin18.2-targeting therapeutic industry. Roche Diagnostics developed the Ventana(R) CLDN18 (43-14A) RxDx Assay, the first immunohistochemistry-based test approved to detect Claudin18.2 expression in patients with G/GEJ adenocarcinoma. This test identifies which patients are most likely to benefit from Vyloy treatment, resulting in more precise and successful therapy selection. As the market for Claudin18.2-targeted therapies grows, the development and implementation of companion diagnostics will be critical in improving treatment results.

Looking ahead, the Claudin18.2-targeting therapy market is expected to increase further, owing to the encouraging results of current medications and a growing pipeline. While G/GEJ malignancies remain the primary focus, research into additional indications may broaden the uses of these therapies. The market's global nature, with strong representation from both Western and Asian enterprises, creates a collaborative and competitive atmosphere that is likely to encourage further innovation. As more therapies are developed and approved, and as companion diagnostics become more widely available, the impact of Claudin18.2-targeted therapies on cancer treatment is expected to grow significantly, offering new hope for patients with difficult-to-treat cancers.

1. Introduction To Claudin 18.2 Therapy

1.1 Understanding Claudin 18.2 Proteins
1.2 Development Of Claudin 18.2 Therapy
1.3 Need For Claudin 18.2 Targeted Therapy

2. Research Advancement Targeting Claudin 18.2 For Cancer Immunotherapy

2.1 Monoclonal Antibody
2.2 Bispecific Antibody
2.3 CAR T Cell Therapy
2.4 Antibody Drug Conjugate

3. Approved Claudin 18.2 Targeting Therapies

4. Vyloy - 1st Approved Claudin 18.2 Targeted Therapy

4.1 Clinical Insight
4.2 Pricing & Dosing Insight
4.3 Sales Insight

5. Global Claudin 18.2 Market Scenario

5.1 Current Market Overview
5.2 Favorable Market Development Parameters
5.3 Key Developmental Challenges
5.4 Future Market Outlook

6. Claudin 18.2 Therapy Trend Analysis By Region

6.1 US
6.2 China
6.3 Europe
6.4 UK
6.5 Japan
6.6 Australia
6.7 South Korea

7. Claudin 18.2 Therapy Clinical Trends & Innovations by Indication

7.1 Gastric Cancer
7.2 Pancreatic Cancer
7.3 Ovarian Cancer
7.4 Lung Cancer

8. Technical & Clinical Platforms For Developing Advanced Claudin 18.2 Therapy

9. Global Claudin 18.2 Drugs Clinical Trials Overview

9.1 By Company
9.2 By Country
9.3 By Indication
9.4 By Patient Segment
9.5 By Phase

10. Global Claudin 18.2 Drugs Clinical Trials By Company, Indication & Phase

10.1 Research
10.2 Preclinical
10.3 Phase 0
10.4 Phase I
10.5 Phase I/II
10.6 Phase II
10.7 Phase III

11. Marketed Claudin 18.2 Drugs Clinical Insight

12. Competitive Landscape

12.1 Abpro Therapeutics
12.2 Antengene Corporation
12.3 Arovella Therapeutics
12.4 Astellas Pharma
12.5 AstraZeneca
12.6 Beijing Mabworks Biotech
12.7 Biotheus
12.8 CARsgen
12.9 Dragonboat Biopharmaceutical
12.10 Gracell Biotechnology
12.11 Harbour BioMed
12.12 Innovent Biologics
12.13 Klus Pharma
12.14 L and L Biopharma
12.15 LaNova Medicines Limited
12.16 Leap Therapeutics
12.17 Luye Pharma Group
12.18 Nanjing Bioheng Biotech
12.19 Nanjing KAEDI Biotech
12.20 OriCell Therapeutics
12.21 Shanghai Junshi Biosciences
12.22 SparX Biopharmaceutical
12.23 TORL Biotherapeutics
12.24 Transcenta Holding

简介目录图表

List of Figures

Figure 1-1: Claudin 18.2 Protein - Functions
Figure 1-2: Functional Classification of the Claudin Family Proteins
Figure 1-3: Dichotomous Role of Claudin 18.2 Protein in Cancer
Figure 1-4: Claudin 18 Isoforms
Figure 1-5: Global - Gastric Cancer Incidences & Deaths (Million), 2022
Figure 2-1: Therapeutic Approach for Claudin 18.2 protein
Figure 2-2: Monoclonal Antibody - Mode of Action
Figure 2-3: Claudin 18.2 - Novel Monoclonal Antibodies in Clinical Research
Figure 2-4: Bispecific Antibody - Advantages
Figure 2-5: PT886 - Phanes Therapeutics Development Vista
Figure 2-6: QLS31905 Phase 1/2 Study - Initiation & Completion Year
Figure 2-7: ASP2138 - Astellas Pharma
Figure 2-8: CARsgen Pharmaceuticals Collaboration - Fudan & Peking University for CT041 & CT048
Figure 2-9: Immunofoco - Pipeline for Claudin 18.2 Therapy
Figure 2-10: NCT06084286 Phase 1 Study - Initiation & Completion Year
Figure 2-11: Claudin 18.2 - ADC Candidates
Figure 2-12: SKB315 - Clinical Trial & Collaboration Overview
Figure 4-1: Vyloy - Approval Year by Region
Figure 4-2: Global - Annual Vyloy Sales (US$ Million), 2024
Figure 4-3: Global - Quarterly Vyloy Sales (US$ Million), Q2-Q3'2024
Figure 5-1: Current Claudin 18.2 Therapy Market - Influencing Factors
Figure 5-2: Global - Claudin 18.2 Targeted Therapy Market, (US$ Million), 2024
Figure 5-3: Global - Claudin 18.2 Targeted Therapy Market, (US$ Million), Q2-Q3'2024
Figure 5-4: Market Drivers for Claudin 18.2 Therapy
Figure 5-5: Market Challenges for Claudin 18.2 Therapy
Figure 5-6: Global - Claudin18.2 Targeted Therapies Market (US$ Million), 2024 - 2029
Figure 5-7: Future Claudin 18.2 Therapy Market - Influencing Factors
Figure 6-1: Triumvira Immunologics - Pipeline for Claudin 18.2 Therapies
Figure 6-2: US - Factors Influencing Claudin 18.2 Therapy Development
Figure 6-3: China - Major Candidates in Clinical Trial
Figure 6-4: LM-302 Phase 2 Study - Initiation & Completion Year
Figure 6-5: TQB2103 Phase 1 Study - Initiation & Completion Year
Figure 6-6: CT048 Phase 1 Study - Initiation & Completion Year
Figure 6-7: SOT102 Phase 1/2 Study - Initiation & Completion Year
Figure 6-8: AZD0901 Phase 2 Study - Initiation & Completion Year
Figure 6-9: AZD5863 Phase 1/2 Study - Initiation & Completion Year
Figure 6-10: SPOTLIGHT Phase 3 Study - Initiation & Completion Year
Figure 6-11: GLOW Phase 3 Study - Initiation & Completion Year
Figure 6-12: ATG-022 Phase 1 Study - Initiation & Completion Year
Figure 7-1: Claudin 18.2 - Upregulation in Gastric Cancer
Figure 7-2: HEC-016 Phase 1 Study - Initiation & Completion Year
Figure 7-3: TJ-CD4B - Structure & Mode of Action
Figure 7-4: Osemitamab Phase 1/2 Study - Initiation & Completion Year
Figure 7-5: SOT102 Phase 1/2 Study - Initiation & Completion Year
Figure 7-6: KD-496 Early Phase 1 Study - Initiation & Completion Year
Figure 7-7: Zolbetuximab Phase 2 Study - Initiation & Completion Year
Figure 7-8: IMC002 Phase 1 Study - Initiation & Completion Year
Figure 7-9: TAC01-CLDN18.2 Phase 1/2 Study - Initiation & Completion Year
Figure 7-10: ZZCART-002 Phase 1 Study - Initiation & Completion Year
Figure 8-1: CARsgen Pharmaceuticals - CycloCAR platform
Figure 8-2: LaNova - LX-ADC(TM) Platform
Figure 8-3: Phanes Therapeutics - PACbody
Figure 8-4: Phanes Therapeutics - SPECpair
Figure 9-1: Global - Claudin 18.2 Drugs Clinical Trials by Company (Numbers), 2024 till 2029
Figure 9-2: Global - Claudin 18.2 Drugs Clinical Trials by Country (Numbers), 2024 till 2029
Figure 9-3: Global - Claudin 18.2 Drugs Clinical Trials by Indication (Numbers), 2024 till 2029
Figure 9-4: Global - Claudin 18.2 Drugs Clinical Trials by Patient Segment (Numbers), 2024 till 2029
Figure 9-5: Global - Claudin 18.2 Drugs Clinical Trials by Phase (Numbers), 2024 till 2029

List of Tables

Table 1-1: Subfamilies of Claudin involved in Different Types of Cancer Formation
Table 2-1: Monoclonal Antibodies Targeting Claudin 18.2 in Clinical Trials
Table 2-2: Bispecific Antibodies Targeting Claudin 18.2 in Clinical Trials
Table 2-3: CAR-T Therapies Targeting Claudin 18.2 in Clinical Trials
Table 2-4: Antibody Drug Conjugates Targeting Claudin 18.2 in Clinical Trials
Table 3-1: Approved Claudin 18.2 Targeting Therapies
Table 4-1: Vyloy - Recommended Dose Modifications in case of Adverse Reactions
Table 5-1: Claudin18.2 Targeting Therapies in Phase 3
Table 6-1: US - Claudin 18.2 Therapies in Ongoing Clinical Trials
Table 6-2: China - Claudin 18.2 Therapies in Ongoing Clinical Trials
Table 6-3: EU - Claudin 18.2 Therapies in Ongoing Clinical Trials
Table 6-4: UK - Claudin 18.2 Therapies in Ongoing Clinical Trials
Table 6-5: Japan - Claudin 18.2 Therapies in Ongoing Clinical Trials
Table 6-6: Australia - Claudin 18.2 Therapies in Ongoing Clinical Trials

Table 6 7: South Korea - Claudin 18.2 Therapies in Ongoing Clinical Trials

Table 7-1: Gastric Cancer - Claudin 18.2 Therapies in Ongoing Clinical Trials
Table 7-2: Pancreatic Cancer - Claudin 18.2 Therapies in Ongoing Clinical Trials

02-2729-4219

+886-2-2729-4219

License/价格

Claudin18.2标靶治疗的全球市场:市场预测和临床试验趋势(2029年)

Global Claudin 18.2 Targeted Therapy Market Forecast & Clinical Trials Insight 2029

目录

第1章 Claudin18.2疗法的简介

第2章作为标的调查的发展癌症免疫疗法的Claudin18.2

第3章已通过核准Claudin18.2标靶治疗

第4章 Vyloy-首个核准的Claudin18.2标靶治疗

第5章全球Claudin18.2市场情势

第6章 Claudin18.2疗法趋势分析，各地区

第7章 Claudin18.2疗法临床趋势与革新，各适应症

第8章为了开发高度的Claudin18.2疗法的技术性及临床性平台

第9章全球Claudin18.2医药品临床试验概要

第10章企业，适应症，各期的全球Claudin18.2医药品临床试验

第11章已上市Claudin18.2药物的临床性洞察

第12章竞争情形